The estimated Net Worth of Anthony C Hooper is at least 2.07 百万$ dollars as of 28 February 2022. Mr. Hooper owns over 40,000 units of Mannkind Corp stock worth over 2,074,355$ and over the last 16 years he sold MNKD stock worth over 0$. In addition, he makes 0$ as Independent Director at Mannkind Corp.
Sign up
Mr. Hooper MNKD stock SEC Form 4 insiders trading
Anthony has made over 8 trades of the Mannkind Corp stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 40,000 units of MNKD stock worth 108,400$ on 28 February 2022.
The largest trade he's ever made was exercising 381,750 units of Mannkind Corp stock on 13 May 2011 worth over 10,994,400$. On average, Anthony trades about 8,445 units every 65 days since 2008. As of 28 February 2022 he still owns at least 338,394 units of Mannkind Corp stock.
You can see the complete history of Mr. Hooper stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anthony Hooper biography
Anthony C. Hooper serves as Independent Director of the Company. Mr. Hooper served as executive vice president of Global Commercial Operations for Amgen Inc. from Oct 2011 until August 2018. During his tenure, he led the transformation of Amgen's commercial organization, placing a relentless focus on putting patients at the center of all the company's activities. Under his leadership, Amgen grew revenue by 50 percent, launched six new first-in-class medicines for serious diseases, more than doubled the global footprint by expanding into 50 new countries, and established a new biosimilars business. Prior to joining Amgen, Hooper spent more than 15 years at Bristol-Myers Squibb. His last role there was senior vice president, Global Commercial Operations and president of the company's $15 billion pharmaceutical business in the Americas, Japan and Intercontinental regions. Previously, he was assistant vice president of Global Marketing for Wyeth Laboratories and led the international marketing group for Lederle International. Mr. Hooper earned law and MBA degrees from the University of South Africa.
How old is Anthony Hooper?
Anthony Hooper is 65, he's been the Independent Director of Mannkind Corp since 2020. There are 4 older and 18 younger executives at Mannkind Corp. The oldest executive at Mannkind Corp is Kent Kresa, 82, who is the Independent Chairman of the Board.
What's Anthony Hooper's mailing address?
Anthony's mailing address filed with the SEC is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108.
Insiders trading at Mannkind Corp
Over the last 20 years, insiders at Mannkind Corp have traded over 14,187,027$ worth of Mannkind Corp stock and bought 107,212,962 units worth 2,707,661,837$ . The most active insiders traders include Alfred E Mann、Juergen Martens、David Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of 3,220,647$. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth 156,500$.
What does Mannkind Corp do?
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
What does Mannkind Corp's logo look like?
Complete history of Mr. Hooper stock trades at AMGEN、BeiGene Ltd、Mannkind Corp、Bristol-Myers Squibb Co
Mannkind Corp executives and stock owners
Mannkind Corp executives and other stock owners filed with the SEC include:
-
Michael Castagna,
Chief Executive Officer, Director -
Dr. Michael E. Castagna Pharm.D.,
CEO & Director -
Stuart Tross,
Chief People and Workplace Officer -
David Thomson,
Executive Vice President, General Counsel, Secretary -
Dr. Michael E. Castagna,
CEO & Director -
Steven Binder,
Chief Financial Officer -
Dr. David B. Thomson,
Exec. VP, Gen. Counsel & Sec. -
Joseph Kocinsky,
Chief Technology Officer -
Steven B. Binder,
Chief Financial Officer -
Joseph Kocinsky M.B.A., M.S.,
Chief Technology Officer -
Dr. Stuart A. Tross,
Chief People & Workplace Officer -
Rosabel Alinaya,
Vice President of Investor Relations, Interim Corporate Controller, Treasurer -
Christine Mundkur,
Independent Director -
Kent Kresa,
Independent Chairman of the Board -
Ronald Consiglio,
Independent Director -
Michael Friedman,
Independent Director -
James Shannon,
Independent Director -
Kevin Kaiserman,
Vice President - Medical Affairs and Safety -
Jennifer Grancio,
Independent Director -
Anthony Hooper,
Independent Director -
Alejandro Galindo M.B.A., M.S.,
Chief Commercial Officer -
James Patrick McCauley Jr., J.D., M.B.A.,
Chief Commercial Officer -
John F. Bedard,
Sr. VP of Worldwide Regulatory Affairs -
Rosabel Realica Alinaya,
VP of Investor Relations & Treasury -
Thomas Hofmann M.D., Ph.D.,
Chief Scientific Officer -
Matthew J Pfeffer,
Corporate VP and CFO -
Henry L Nordhoff,
Director -
David Mac Callum,
Director -
Raymond W. Urbanski,
Corp VP, CMO -
David M Kendall,
Chief Medical Officer -
Elizabeth Garrett Ingram,
Chief Marketing Officer -
Courtney Barton,
Chief Compl & Privacy Officer -
Patrick Mc Cauley,
Chief Commercial Officer -
John R. Riesenberger,
VP & Chief Commercial Officer -
Richard L Anderson,
VP & CFO -
Heather Hay Murren,
Director -
Kathleen Connell,
Director -
Llew Keltner,
Director -
Dan Burns,
VP & President, MKBP -
W Wendell Cheatham,
VP, Medical & Reg Affairs -
Juergen Martens,
Corporate VP -
Hakan Edstrom,
President & COO -
Alfred E Mann,
Chairman & CEO -
Diane Palumbo,
Vice President, Human Resource -
Abraham E Cohen,
Director -
Peter C Richardson,
Chief Scientific Officer -
Lauren M Sabella,
EVP Chief Operating Officer -
Alejandro Galindo,
EVP Endocrine Business Unit -
Burkhard Blank,
EVP Chief Medical Officer -
Sanjay R Singh,
EVP Technical Operations -
Christopher B Prentiss,
Chief Financial Officer -
Sabrina Kay,